Share

RECIST news and updates

Hear Lesley Seymour and Jan Bogaerts  discuss with Helen Saul of EJC News the challenges and possibilities for RECIST

The RECIST Working Group was established in 1995 to review the objective response criteria in use at the time and to explore the utility of the use of unidimensional measurements in response assessment, as proposed by NCIC CTG. The initial working group was led by academic members of the EORTC, NCIC CTG and NCI (USA), with a database being created and maintained under the governance of the EORTC. Over the years, the membership of the Working Group was expanded to include other interested or expert members, including some representation from the pharmaceutical industry, as original members joined pharma, or expertise was identified. RECIST v1 was successfully implemented in 2000, and an update (RECIST 1.1) was released in 2009.

At the TAT Congress held in Paris on 2-4 March 2015, Lesley Seymour (NCIC Clinical Trials Group, Canada and co-chair of the RECIST Working Group) and Jan Bogaerts (Methodology Director EORTC Headquarters in Brussels) respectively chaired and spoke at a ‘Beyond RECIST’ session.

Visit the RECIST Working Group website.

Back to news list

Related News

  • EORTC strategic meeting with Middle Eastern Ambassadors

  • EORTC Quality of Life Group projects to be presented at ISOQOL 2023

  • Celebrating Sarcoma Awareness Month with the start of EU-funded STREXIT 2 project study

  • “Best Proposal in Medicine” award received by EORTC at the PTCOG 61 Conference

  • Long-term efficacy and safety outcomes of the EORTC/LYSA/FIL H10 trial assessing early PET-scan adapted treatment of limited stage Hodgkin lymphoma

  • Joint Statement: health organisations define EHDS’ opt out required for life saving research

  • Congratulations to Dr. Hans Wildiers, winner of the B.J. Kennedy Geriatric Oncology Award

  • Full validation of the EORTC CAT Core

  • SISAQOL-IMI: Setting standards for the use of patient-reported outcome data in cancer trials

  • Synthesis of minimally important differences for interpreting EORTC QLQ-C30 change scores across nine cancer types